By studying the effect of Buzhong Yiqi Decoction（补中益气汤）on the endoplasmic reticulum stress of A549 cells and A549/DDP cells through Nrf2/ROSpathway，the molecular mechanism of Buzhong Yiqi Decoction improving cisplatin resistance in non-small cell lung cancer was investigated.

The serum containing Buzhong Yiqi Decoction was prepared and A549 cells and A549/DDP cells were cultured. They were randomly divided into group A（A549 cells），Group B（A549 cells+20μg/mL cisplatin），group C（A549 cells+20μg/mL cisplatin+10% Buzhong Yiqi Decoction-containing serum），group D（A549/DDP cells），group E（A549/DDP cells+20μg/mL cisplatin）and group F（A549/DDP cells+20μg/mL cisplatin+10% Buzhong Yiqi Decoction-containing serum）. Half inhibitory concentration of cisplatin（IC₅₀）was detected by CCK-8 method，and reactive oxygen species（ROS）were detected by DCFH-DA fluorescent probe method. The protein expression levels of Nrf2，P-Nrf2，PERK，P-PERK，eIF2α，P-eIF2α，IRE1 and XBP1 were detected by Western blot.

In both A549 cells and A549/DDP cells，Buzhong Yiqi Decoction significantly decreased the IC₅₀ value of cisplatin（P<0.05）. In both cells，cisplatin could up-regulate the protein expressions of Nrf2 and P-Nrf2，and after the intervention of Buzhong Yiqi Decoction，the expression levels of both were down-regulated（P<0.05）in A549/DDPcells compared with those in A549 cells（P<0.05）. Compared with the blank group，cisplatin could up-regulate the ROSexpression of the two cells（P<0.05），the ROS expression was further up-regulated after combined with Buzhong Yiqi Decoction（P<0.05），and the ROSexpression level of A549 cells was significantly higher than that of A549/DDP cells（P<0.05）. There were no significant differences in the expressions of PERK and eIF2αamong all groups（P>0.05）. Cisplatin significantly up-regulated the protein expressions of PPERK，P-eIF2α，IRE1 and XBP1 in the two cell lines，and the expression was up-regulated again after the intervention of Buzhong Yiqi Decoction（P<0.05），and the expression of ER stress protein in A549 cells was higher than that in A549/DDP cells（P<0.05）.

Buzhong Yiqi Decoction may improve cisplatin resistance of A549 cells and A549/DDP cells by regulating ERSthrough Nrf2/ROSsignal pathway.

To analyze the correlation of the distribution of TCM syndromes in patients with sepsis-induced lung injury and lung injury-related indicators and sequential organ failure assessment（SOFA），acute physiology and chronic health evaluation Ⅱ（APACHE Ⅱ）score.

Eighty patients with sepsis-induced lung injury admitted to the hospital from January 2022 to January 2023 were selected. The general data，lung injury-related indicators｛arterial oxygenation index（PaO₂/FiO₂），alveolar arterial oxygen partial pressure difference［P（A-a）O₂］｝and SOFA and APACHE Ⅱ scores of the patients were collected. The patients with sepsis-induced lung injury were classified according to the classification criteria of traditional Chinese medicine. The above observation indexes of patients with sepsis-induced lung injury of different types were compared and the correlation was analyzed.

Among the patients with sepsis-induced lung injury，the lung heat obstruction type accounted for the highest proportion［35.00%（28/80）］，followed by the blood stasis type［27.50%（22/80）］，the lung obstruction type［23.75%（19/80）］，and the water retention type［13.75%（11/80）］. There was no significant difference in gender or age among patients with different syndromes（P>0.05）. There were statistically significant differences in PaO₂/FiO₂ and P（A-a）O₂ among patients with different syndromes（P<0.05）. There were significant differences in SOFA and APACHE Ⅱ scores among patients with different syndromes（P<0.05）. There was a significant negative correlation of PaO₂/FiO₂ and lung heat obstruction，blood stasis obstructing lung，lung congestion and Fu-organ excess，water retention and lung depression（P<0.05），and a significant positive correlation with P（A-a）O₂，SOFA score and APACHE Ⅱ score（P<0.05）.

The TCM syndromes of patients with sepsis-induced lung injury are mainly lung heat obstruction，blood stasis obstructing lung，lung congestion and Fu-organ excess，water retention obstructing lung，which are closely related to lung injury-related indicators and SOFA and APACHE Ⅱ scores. Mastering the characteristics of syndrome differentiation of sepsis-induced lung injury and observing the changes of lung injury-related indicators and SOFA and APACHE Ⅱ scores have high value for disease diagnosis，treatment and prognosis evaluation.

To investigate the clinical prognostic effect of Wenyang Sanjie Decoction（温阳散结汤）combined with immunotherapy on patients of epidermal growth factor receptor（EGFR）mutated advanced non-small cell lung cancer（NSCLC）.

Ninety-three NSCLCpatients with EGFR mutation admitted to the hospital from January 2019 to January 2023 were selected as study subjects，and all patients received the same chemotherapy regimen. Forty patients treated with immune checkpoint inhibitors（ICIs）were selected as the control group，and the other 53 patients treated with Wenyang Sanjie Decoction combined with ICIs were selected as the observation group. Tumor response，tumor markers and quality of life before and after treatment were compared between the two groups. The occurrence of toxic and side effects was compared.

The disease control rate（DCR）and objective response rate（ORR）of the observation group were 98.11% and 66.04%，respectively，and those of the control group were 95.00% and 65.00%，respectively. There was no significant difference in short-term efficacy between the groups（P>0.05）. After treatment，the levels of carbohydrate antigen 125（CA125）and carcinoembryonic antigen（CEA）in both groups were significantly lower than those before treatment（P<0.05），but there was no statistical significance between two groups（P>0.05）. After treatment，the total score of the observation group was significantly lower than that of the control group（P<0.05），and there was no significant difference between the two groups（P>0.05）. The total incidence of toxic and side effects was 32.08% in observation group and 47.50% in control group（P>0.05）.

Wenyang Sanjie Decoction combined with immunotherapy for advanced NSCLCwith EGFR mutation is effective in improving the symptoms of traditional Chinese medicine and has a high safety，suitable for promotion.

To explore the therapeutic effect of Bufei Xichuan Decoction（补肺息喘汤）on stable stage chronic obstructive pulmonary disease（SCOPD）patients and its impact on the levels of inflammatory factors，Toll like receptor 4（TLR4）and chemokine CXC ligand 13（CXCL13）in patients.

A total of 160 SCOPD patients from April 2022 to April 2024 in the hospital were divided into observation group and control group，each with 80 cases. The patients of the control group inhaled indatelopram bromide，while those of the observation group took Bufei Xichuan Decoction on the basis of the control group. The treatment period for both groups was 8 weeks. The therapeutic effects of two groups was compared. The changes in lung function，6-minute walking distance（6MWT），COPD assessment test（CAT）questionnaire scores，inflammatory factors，TLR4 and CXCL13 before and after treatment were compared.

The effective rate of the observation group was higher than that of the control group（P<0.05）. After 8 weeks of treatment，the values of FEV1/FVC，PEF，FEV1 and 6MWT of the two groups were higher than those before treatment，while the CAT score，the levels of tumor necrosis factor-α（TNF-α），interleukin-6（IL-6），interleukin-8（IL-8），TLR4 and CXCL13 were lower than those before treatment（P<0.05）. The values of FEV1/FVC，PEF，FEV1 and 6MWT of the observation group were higher than those of the control group，while the CAT score，the levels of TNF-α，IL-6，IL-8，TLR4 and CXCL13 were lower than those of the control group after treatment（P<0.05）.

-Bufei Xichuan Decoction has a significant therapeutic effect on SCOPD patients，reducing cellular inflammatory response and lowering the levels of TLR4 and CXCL13，which is worthy of clinical reference.

To investigate the effect of Buzhong Yiqi Decoction（补中益气汤）on immune function and prognosis of elderly patients undergoing laparoscopic inguinal hernia repair.

Ninety-six elderly patients with inguinal hernia admitted to the hospital were selected and randomly divided into two groups，48 cases in each group. Both groups received laparoscopic inguinal hernia repair. The control group received anti-infection treatment on the basis of this and the observation group was combined with Buzhong Yiqi Decoction on the basis of the control group for 7 days. The clinical therapeutic effect，immune function，visual analogue score（VAS）score，exhaust time，time of getting out of bed，length of hospital stay and postoperative complications of the two groups were compared.

The total effective rate of the control group（87.50%）was significantly lower than that of the observation group（97.92%），with statistical significance（P<0.05）. After 3 days of treatment，VASscores in both groups were significantly lower than those before treatment（P<0.05）. There was no statistical difference between the groups. After 7 days of treatment，VASscores of both groups were significantly lower than those before treatment and 3 days after treatment，and the score of the observation group was significantly lower than that of the control group（P<0.05）. The levels of immunoglobulin G（IgG），immunoglobulin A（IgA）and immunoglobulin M（IgM）in both groups were significantly increased after treatment compared with those before treatment（P<0.05），and the improvement in the observation group was significantly better than that in the control group（P<0.05）. Anal exhaust，postoperative getting out of bed and postoperative hospitalization time in the observation group were better than those in the control group（P<0.05）. The complication rate was 14.59% in the control group and 2.08% in the observation group. The complication rate in the observation group was significantly lower than that in the control group（P<0.05）.

Buzhong Yiqi Decoction has a good therapeutic effect on the elderly patients undergoing laparoscopic inguinal hernia repair. It can improve the immune function，promote the rehabilitation，reduce the complications，and has high safety. It is worthy of clinical application.

To investigate the mechanism of Yixiao Ointment（一效膏）in promoting the healing of skin ulcers in diabetic rats by inhibiting pyroptosis.

Seventy-two male SD rats of SPF grade were randomly divided into blank group and model group，and the diabetes model was induced by high-fat and high-sugar chow combined with small-dose streptozotocin（STZ）intraperitoneal injection in the model group. One month later，the rats in each group were cut into the skin to create open wounds to construct the diabetic rat ulcer model. After successful modeling，the model group was divided into a model control group（physiological sodium chloride injection），a Yixiao Ointment group（Yixiao Ointment）and an epidermal growth factor group（human epidermal growth factor gel）with 18 rats in each group. After intervention for 14 consecutive days，the healing of skin ulcerations was observed. Enzyme-linked immunosorbent assay（ELISA）was used for detecting the expression levels of interleukin-1（IL-1），interleukin-18（IL-18）and tumor necrosis factor-α（TNF-α）in serum，and the protein levels and mRNA expression levels of NOD-like receptor thermoprotein structural domain-associated protein 3（NLRP3），cysteine protease-1（Caspase-1），nuclear factorκB（NF-κB），apoptosis-associated speck-like protein（ASC）were detected by Western blot and reverse transcription-polymerase chain reaction（RT-PCR）.

Visual observation of the ulcer surface showed that the ulcerated skin of rats in the Yixiao Ointment group healed significantly. Compared with those of the model control group，the levels of IL-1，IL-18 and TNF-αwere significantly decreased in the Yixiao Ointment group，and the protein expressions of NLRP3，Caspase-1，NF-κB and ASCwere decreased in the Yixiao Ointment group.

Yixiao Ointment can promote the healing of diabetic ulcerated skin，and its mechanism of action may be related to its ability to reduce the inflammatory response and inhibit cellular death.

To analyze the chemical composition and contents of Zhishi（Aurantii Immaturus Fructus）-Baizhu（Atractylodis Macrocephalae Rhizoma）essential oil（ZBEO）and explore the acute toxicity of different doses of chemical constituents of ZBEOin mice.

GC-MSwas used to analyze and identify the chemical composition. After oral administration of jojoba oil and ZBEO，the activity，diet，water intake，body weight，mortality and other conditions of the mice were observed. The values of median lethal dose（LD₅₀）and 95% confidence interval were calculated by using the weighted regression method（Bliss）.

Through GC-MS analysis，a total of 10 chemical components were identified in ZBEO，accounting for 46.41% of the total oil content. The main components were curzerenone，D-limonene，β-pinene，γ-elemene，atractylenolide Ⅱ，β-elinene and trans-caryophyllene. The toxicity experiment of ZBEO on mice showed no significant effects on the diet，water intake or body weight of the surviving mice. The value of LD₅₀ of ZBEO was calculated to be 1.681 mL/kg by using the Bliss method，indicating a certain level of toxicity. The 95% confidence interval for LD₅₀ was 3.367～7.417 mL/kg. The regression equation was Y（Probit）＝-1.228+7.612 lgD.

Curzerenone and D-limonene are the main components of ZBEO. The essential oil exhibits a certain level of toxicity，mainly affecting the blood vessels as indicated by organ index and pathological observations. The main affected organs are liver，spleen and kidney. The toxicity is dose-dependent，and within a certain dosage range，it can be safely used.

To observe the clinical efficacy of Modified Erchen Decoction（二陈汤加减）in the treatment of nonalcoholic fatty liver disease，and analyze the impact of this treatment on liver function，blood lipids and other indicators in patients.

The clinical data of 80 patients with non-alcoholic fatty liver disease admitted to Dongguan Hospital of Guangzhou University of Chinese Medicine from January 2022 to June 2023 were collected. They were randomly divided into a control group and an observation group，with 40 patients in each group. The patients of the control group were treated with Atorvastatin Calcium Tablets. Those of the observation group were treated with Modified Erchen Decoction on the basis of the control group. The clinical efficacy，liver function，blood lipid levels and changes in inflammatory markers were observed and compared between the two groups.

The effective rate of the control group was 75.00%（30/40），while that of the observation group was 92.50%（37/40）. Compared with that of the control group，the effective rate of the observation group significantly increased，with a statistically significant difference（P<0.05）. After treatment，the levels of aspartate aminotransferase（AST），alanine aminotransferase（ALT）and total bilirubin in serum（TBIL）in the observation group significantly decreased compared to those in the control group（P<0.01）. There was no significant difference in values of controlled attenuation parameter（cap）or body mass index（BMI）between the two groups before administration（P>0.05）. After the intervention，the values of CAPand BMI of the observation group significantly decreased compared to those of the control group（P<0.01）. There was no significant difference in blood lipid levels between the two groups before administration（P>0.05）. After intervention，compared to those of the control group，the levels of triglycerides（TG），low density lipoprotein cholesterol（LDL-C）and total cholesterol（TC）of the observation group patients were significantly reduced，while the high density lipoprotein cholesterol（HDL-C）levels were significantly upregulated，with statistically significant differences（P<0.05，P<0.01）. There was no significant difference in the levels of inflammatory indicators between the two groups before administration（P>0.05）. After intervention，compared to those of the control group，the levels of IL-6，tumor necrosis factor-α（TNF-α）and hypersensitive C-reactive protein（hs-CRP）in the observation group were significantly decreased than those in the control group（P<0.05）. There were 4 cases of adverse reactions in the control group，with an incidence rate of 10.00%（4/40），and 3 cases in the observation group，with an incidence rate of 7.50%（3/40）. There was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）.

The combination of Modified Erchen Decoction and conventional Western medicine treatment can not only improve the clinical efficacy of NAFLD，improve liver function，reduce blood lipid levels，but also delay the process of liver fibrosis，inhibit the level of inflammation in the body，and improve the patients'condition without increasing adverse reactions.